{
  "_metadata": {
    "version": "2.1",
    "ticker": "EWTX",
    "asset_name": "Sevasemten",
    "extraction_date": "2026-02-11",
    "source_id": "ewtx_edgewise_therapeutics_jp_morgan_presentation_2026_vfinal_pdf"
  },
  "asset": {
    "name": "Sevasemten",
    "company": "Edgewise Therapeutics",
    "ticker": "EWTX",
    "stage": "Pivotal",
    "modality": "Small molecule",
    "ownership": "Wholly-owned",
    "one_liner": "Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor designed to protect dystrophic muscle against contraction-induced injury in Becker muscular dystrophy, potentially becoming the first approved therapy for this devastating disease."
  },
  "target": {
    "name": "Fast skeletal myosin ATPase",
    "full_name": "Fast skeletal muscle myosin ATPase",
    "class": "Motor protein",
    "pathway": "Muscle contraction",
    "biology": {
      "simple_explanation": "In Becker muscular dystrophy, progressive contraction-induced muscle damage results in loss of skeletal muscle function and severe disability. Sevasemten targets fast myosin to protect dystrophic muscle against this contraction-induced injury, intended to minimize progressive muscle damage that leads to functional impairment.",
      "pathway_detail": "Fast skeletal myosin ATPase drives muscle contraction. In dystrophic muscle, excessive contraction causes damage and progressive loss of function.",
      "downstream_effects": [
        "Reduced contraction-induced muscle damage",
        "Preservation of muscle function",
        "Prevention of progressive functional decline"
      ]
    },
    "why_good_target": {
      "clinical_validation": "Significant clinical experience with durable response, well tolerated across multiple trials with longest exposure over 4 years",
      "genetic_validation": {
        "gain_of_function": null,
        "loss_of_function": "Becker is caused by mutations in the dystrophin gene leading to reduced/abnormal dystrophin protein, making muscle vulnerable to contraction-induced damage"
      },
      "source": {
        "id": "ewtx_edgewise_therapeutics_jp_morgan_presentation_2026_vfinal_pdf",
        "slide": 9,
        "verified": false
      }
    }
  },
  "mechanism": {
    "type": "Fast skeletal myosin inhibitor",
    "how_it_works": "Sevasemten inhibits fast skeletal myosin ATPase to reduce the force of muscle contractions, thereby protecting dystrophic muscle fibers from contraction-induced damage that leads to progressive muscle breakdown and functional impairment",
    "differentiation": "First-in-class fast skeletal myosin inhibitor with novel mechanism of action that addresses the root cause of muscle breakdown in Becker muscular dystrophy, with oral administration and generally safe and well tolerated profile",
    "source": {
      "id": "ewtx_edgewise_therapeutics_jp_morgan_presentation_2026_vfinal_pdf",
      "slide": 8,
      "verified": false
    }
  },
  "regulatory": {
    "designations": [
      {
        "type": "Orphan Drug Designation (FDA)",
        "indication": "Becker muscular dystrophy",
        "date_granted": null,
        "source": {
          "id": "ewtx_canyon_2024",
          "slide": null,
          "verified": false
        }
      },
      {
        "type": "Orphan Drug Designation (FDA)",
        "indication": "Duchenne muscular dystrophy",
        "date_granted": null,
        "source": {
          "id": "ewtx_canyon_2024",
          "slide": null,
          "verified": false
        }
      },
      {
        "type": "Fast Track Designation (FDA)",
        "indication": "Becker muscular dystrophy",
        "date_granted": null,
        "source": {
          "id": "ewtx_canyon_2024",
          "slide": null,
          "verified": false
        }
      },
      {
        "type": "Fast Track Designation (FDA)",
        "indication": "Duchenne muscular dystrophy",
        "date_granted": null,
        "source": {
          "id": "ewtx_canyon_2024",
          "slide": null,
          "verified": false
        }
      },
      {
        "type": "Rare Pediatric Disease Designation (FDA)",
        "indication": "Duchenne muscular dystrophy",
        "date_granted": null,
        "source": {
          "id": "ewtx_canyon_2024",
          "slide": null,
          "verified": false
        }
      },
      {
        "type": "Orphan Drug Designation (EMA)",
        "indication": "Becker muscular dystrophy",
        "date_granted": null,
        "source": {
          "id": "ewtx_canyon_2024",
          "slide": null,
          "verified": false
        }
      },
      {
        "type": "Orphan Drug Designation (EMA)",
        "indication": "Duchenne muscular dystrophy",
        "date_granted": null,
        "source": {
          "id": "ewtx_canyon_2024",
          "slide": null,
          "verified": false
        }
      }
    ],
    "planned_pathway": {
      "type": "Traditional NDA",
      "surrogate_endpoint": "NDA submission for sevasemten in Becker planned following GRAND CANYON pivotal trial readout",
      "source": {
        "id": "ewtx_edgewise_therapeutics_jp_morgan_presentation_2026_vfinal_pdf",
        "slide": 29,
        "verified": false
      }
    }
  },
  "partnership": {
    "_note": "Wholly-owned; no partnership",
    "partner": null,
    "territory": null,
    "economics": null
  },
  "pharmacology": {
    "pk_parameters": {
      "half_life": {
        "value": null,
        "population": null,
        "source": {
          "id": "ewtx_edgewise_therapeutics_jp_morgan_presentation_2026_vfinal_pdf",
          "slide": null,
          "verified": false
        }
      },
      "cmax": {
        "value": null,
        "source": {
          "id": "ewtx_edgewise_therapeutics_jp_morgan_presentation_2026_vfinal_pdf",
          "slide": null,
          "verified": false
        }
      },
      "auc": {
        "value": null,
        "source": {
          "id": "ewtx_edgewise_therapeutics_jp_morgan_presentation_2026_vfinal_pdf",
          "slide": null,
          "verified": false
        }
      },
      "tmax": {
        "value": null,
        "source": {
          "id": "ewtx_edgewise_therapeutics_jp_morgan_presentation_2026_vfinal_pdf",
          "slide": null,
          "verified": false
        }
      },
      "bioavailability": {
        "value": "Oral (bioavailability not specified)",
        "source": {
          "id": "ewtx_edgewise_therapeutics_jp_morgan_presentation_2026_vfinal_pdf",
          "slide": null,
          "verified": false
        }
      },
      "volume_of_distribution": {
        "value": null,
        "source": {
          "id": "ewtx_edgewise_therapeutics_jp_morgan_presentation_2026_vfinal_pdf",
          "slide": null,
          "verified": false
        }
      }
    },
    "dose_response": {
      "doses_tested": "10mg PO daily in pivotal trial",
      "dose_rationale": null,
      "exposure_response": null,
      "recommended_dose": {
        "dose": "10mg PO daily",
        "rationale": "Dose used in pivotal GRAND CANYON trial",
        "source": {
          "id": "ewtx_edgewise_therapeutics_jp_morgan_presentation_2026_vfinal_pdf",
          "slide": 14,
          "verified": false
        }
      },
      "by_dose": null
    },
    "target_engagement": {
      "metric": "CK (creatine kinase) reduction from baseline \u2014 biomarker of muscle damage",
      "by_dose": null
    },
    "pk_summary": "Orally administered with daily dosing"
  },
  "indications": {
    "lead": {
      "name": "Becker muscular dystrophy",
      "patient_population": "Adult individuals with Becker muscular dystrophy with NSAA score 5-32, not taking corticosteroids",
      "current_penetration": "No FDA approved therapies currently exist for Becker muscular dystrophy",
      "rationale": "Becker is a rare, genetic, life-shortening, debilitating and degenerative neuromuscular disease with progressive contraction-induced muscle damage resulting in loss of skeletal muscle function and severe disability",
      "source": {
        "id": "ewtx_edgewise_therapeutics_jp_morgan_presentation_2026_vfinal_pdf",
        "slide": 7,
        "verified": false
      }
    },
    "expansion": [
      {
        "name": "Duchenne muscular dystrophy",
        "stage": "Phase 3 planning",
        "rationale": "Reported positive LYNX and FOX Phase 2 results in Duchenne",
        "source": {
          "id": "ewtx_edgewise_therapeutics_jp_morgan_presentation_2026_vfinal_pdf",
          "slide": 4,
          "verified": false
        }
      }
    ]
  },
  "clinical_data": {
    "trials": [
      {
        "name": "Phase 1 24-month Open Label Study",
        "nct_id": null,
        "phase": "Phase 1",
        "status": "Completed",
        "design": "24-month open label study",
        "enrollment": "N=12",
        "arms": [
          {
            "name": "Sevasemten",
            "dose": null,
            "n": 12
          }
        ],
        "primary_endpoint": {
          "name": "Safety and tolerability",
          "definition": "Safety and tolerability assessment",
          "result": "Durable response, 11 of 12 remain on therapy, longest exposure +4 years, well tolerated",
          "source": {
            "id": "ewtx_edgewise_therapeutics_jp_morgan_presentation_2026_vfinal_pdf",
            "slide": 9,
            "verified": false
          }
        },
        "secondary_endpoints": [],
        "biomarkers": [],
        "safety": {
          "summary": "Well tolerated with durable response, 11 of 12 patients remain on therapy with longest exposure over 4 years",
          "key_aes": null,
          "discontinuations": "1 of 12 patients discontinued",
          "saes": null,
          "deaths": null
        },
        "source": {
          "id": "ewtx_edgewise_therapeutics_jp_morgan_presentation_2026_vfinal_pdf",
          "slide": 9,
          "verified": false
        }
      },
      {
        "name": "Phase 2 16-week Placebo Controlled Exercise Challenge Study",
        "nct_id": null,
        "phase": "Phase 2",
        "status": "Completed",
        "design": "16-week placebo controlled exercise challenge study",
        "enrollment": "N=9",
        "arms": [
          {
            "name": "Sevasemten",
            "dose": null,
            "n": null
          },
          {
            "name": "Placebo",
            "dose": null,
            "n": null
          }
        ],
        "primary_endpoint": {
          "name": "Biomarkers of muscle damage",
          "definition": "Reduction in biomarkers of muscle damage vs placebo",
          "result": "Significant reduction in biomarkers of muscle damage vs placebo",
          "source": {
            "id": "ewtx_edgewise_therapeutics_jp_morgan_presentation_2026_vfinal_pdf",
            "slide": 9,
            "verified": false
          }
        },
        "secondary_endpoints": [],
        "biomarkers": [
          {
            "name": "Muscle damage biomarkers",
            "result": "Significant reduction vs placebo",
            "clinical_significance": "Indicates reduced muscle damage from contractions",
            "source": {
              "id": "ewtx_edgewise_therapeutics_jp_morgan_presentation_2026_vfinal_pdf",
              "slide": 9,
              "verified": false
            }
          }
        ],
        "safety": {
          "summary": "Well tolerated",
          "key_aes": null,
          "discontinuations": null,
          "saes": null,
          "deaths": null
        },
        "source": {
          "id": "ewtx_edgewise_therapeutics_jp_morgan_presentation_2026_vfinal_pdf",
          "slide": 9,
          "verified": false
        }
      },
      {
        "name": "Phase 2 12-month Placebo Controlled Study",
        "nct_id": null,
        "phase": "Phase 2",
        "status": "Completed",
        "design": "12-month placebo controlled study",
        "enrollment": "N=40 Adults",
        "arms": [
          {
            "name": "Sevasemten",
            "dose": null,
            "n": null
          },
          {
            "name": "Placebo",
            "dose": null,
            "n": null
          }
        ],
        "primary_endpoint": {
          "name": "Creatine kinase (CK)",
          "definition": "Reduction in CK levels",
          "result": "Met primary endpoint reduction in CK",
          "source": {
            "id": "ewtx_edgewise_therapeutics_jp_morgan_presentation_2026_vfinal_pdf",
            "slide": 9,
            "verified": false
          }
        },
        "secondary_endpoints": [
          {
            "name": "NSAA stability",
            "result": "NSAA stable over time with trend toward improvement vs placebo",
            "source": {
              "id": "ewtx_edgewise_therapeutics_jp_morgan_presentation_2026_vfinal_pdf",
              "slide": 9,
              "verified": false
            }
          }
        ],
        "biomarkers": [
          {
            "name": "Creatine kinase (CK)",
            "result": "Significant reduction vs placebo",
            "clinical_significance": "CK is a biomarker of muscle damage; reduction indicates muscle protection",
            "source": {
              "id": "ewtx_edgewise_therapeutics_jp_morgan_presentation_2026_vfinal_pdf",
              "slide": 9,
              "verified": false
            }
          }
        ],
        "safety": {
          "summary": "Well tolerated",
          "key_aes": null,
          "discontinuations": null,
          "saes": null,
          "deaths": null
        },
        "source": {
          "id": "ewtx_edgewise_therapeutics_jp_morgan_presentation_2026_vfinal_pdf",
          "slide": 9,
          "verified": false
        }
      },
      {
        "name": "GRAND CANYON Pivotal Trial",
        "nct_id": null,
        "phase": "Pivotal",
        "status": "Ongoing",
        "design": "18-month placebo controlled global registrational study",
        "enrollment": "N=175 Adults",
        "arms": [
          {
            "name": "Sevasemten",
            "dose": "10mg PO daily",
            "n": null
          },
          {
            "name": "Placebo",
            "dose": "Placebo",
            "n": null
          }
        ],
        "primary_endpoint": {
          "name": "NSAA at 18 months",
          "definition": "North Star Ambulatory Assessment score at 18 months",
          "result": "Powered at >98% for observing a significant difference assuming a mean NSAA difference of 1.7 points over placebo at 18 months",
          "source": {
            "id": "ewtx_edgewise_therapeutics_jp_morgan_presentation_2026_vfinal_pdf",
            "slide": 14,
            "verified": false
          }
        },
        "secondary_endpoints": [
          {
            "name": "Timed function tests",
            "result": "Pending",
            "source": {
              "id": "ewtx_edgewise_therapeutics_jp_morgan_presentation_2026_vfinal_pdf",
              "slide": 14,
              "verified": false
            }
          },
          {
            "name": "Patient reported outcomes",
            "result": "Pending",
            "source": {
              "id": "ewtx_edgewise_therapeutics_jp_morgan_presentation_2026_vfinal_pdf",
              "slide": 14,
              "verified": false
            }
          }
        ],
        "biomarkers": [
          {
            "name": "Biomarkers of muscle damage",
            "result": "Pending",
            "clinical_significance": "Will assess muscle protection effects",
            "source": {
              "id": "ewtx_edgewise_therapeutics_jp_morgan_presentation_2026_vfinal_pdf",
              "slide": 14,
              "verified": false
            }
          }
        ],
        "safety": {
          "summary": "Ongoing assessment",
          "key_aes": null,
          "discontinuations": null,
          "saes": null,
          "deaths": null
        },
        "source": {
          "id": "ewtx_edgewise_therapeutics_jp_morgan_presentation_2026_vfinal_pdf",
          "slide": 14,
          "verified": false
        }
      },
      {
        "name": "MESA Open Label Extension",
        "nct_id": null,
        "phase": "Extension",
        "status": "Ongoing",
        "design": "Open-label extension study in adults/adolescents with Becker",
        "enrollment": "99% of eligible Becker trial participants enrolled",
        "arms": [
          {
            "name": "Sevasemten",
            "dose": null,
            "n": null
          }
        ],
        "primary_endpoint": {
          "name": "Long-term safety and efficacy",
          "definition": "Long-term assessment",
          "result": "Sustained stability over 3 years vs predicted -4.4 point decline",
          "source": {
            "id": "ewtx_edgewise_therapeutics_jp_morgan_presentation_2026_vfinal_pdf",
            "slide": 11,
            "verified": false
          }
        },
        "secondary_endpoints": [
          {
            "name": "NSAA score maintenance",
            "result": "NSAA score at 3 years: +0.2 vs predicted decrease of -4.4 points",
            "source": {
              "id": "ewtx_edgewise_therapeutics_jp_morgan_presentation_2026_vfinal_pdf",
              "slide": 11,
              "verified": false
            }
          }
        ],
        "biomarkers": [],
        "safety": {
          "summary": "Well tolerated long-term with high retention rate",
          "key_aes": null,
          "discontinuations": null,
          "saes": null,
          "deaths": null
        },
        "source": {
          "id": "ewtx_edgewise_therapeutics_jp_morgan_presentation_2026_vfinal_pdf",
          "slide": 11,
          "verified": false
        }
      }
    ]
  },
  "differentiation_claims": [
    {
      "claim": "First-in-class fast skeletal myosin inhibitor",
      "evidence_level": "management_claim",
      "caveat": null,
      "source": {
        "id": "ewtx_jpm_2026",
        "slide": null,
        "verified": false
      }
    },
    {
      "claim": "Only drug in pivotal development for Becker muscular dystrophy \u2014 zero FDA-approved therapies exist",
      "evidence_level": "management_claim",
      "caveat": null,
      "source": {
        "id": "ewtx_jpm_2026",
        "slide": null,
        "verified": false
      }
    },
    {
      "claim": "Sustained NSAA stabilization after 3 years in MESA OLE, diverging from natural history decline",
      "evidence_level": "cross_trial",
      "caveat": "Open-label data; comparison to natural history studies, not concurrent placebo; small N (85 participants)",
      "source": {
        "id": "ewtx_mesa_2025",
        "slide": null,
        "verified": false
      }
    },
    {
      "claim": "Oral administration \u2014 convenient dosing for chronic disease",
      "evidence_level": "management_claim",
      "caveat": null,
      "source": {
        "id": "ewtx_jpm_2026",
        "slide": null,
        "verified": false
      }
    }
  ],
  "competitive_landscape": {
    "competitors": [],
    "_note": "No FDA approved therapies currently exist for Becker muscular dystrophy, representing a first-in-disease opportunity"
  },
  "ip_landscape": {
    "composition_of_matter": {
      "patent_expiry": null,
      "source": {
        "id": "ewtx_edgewise_therapeutics_jp_morgan_presentation_2026_vfinal_pdf",
        "slide": null,
        "verified": false
      }
    },
    "method_of_use": {
      "patent_expiry": null,
      "source": {
        "id": "ewtx_edgewise_therapeutics_jp_morgan_presentation_2026_vfinal_pdf",
        "slide": null,
        "verified": false
      }
    },
    "regulatory_exclusivity": {
      "type": "Orphan Drug (FDA + EMA for both Becker and Duchenne); Rare Pediatric Disease (Duchenne); Fast Track (Becker + Duchenne)",
      "expiry": null
    },
    "freedom_to_operate": null
  },
  "market_opportunity": {
    "tam": "~$5 Billion total potential Becker market",
    "patient_population": "~6,000 Becker patients in the US; >12,000 in major markets",
    "unmet_need": "Zero FDA approved therapies for a devastating, genetic, life-shortening, debilitating and degenerative neuromuscular disease",
    "pricing_benchmark": null,
    "peak_sales_estimate": null,
    "source": {
      "id": "ewtx_edgewise_therapeutics_jp_morgan_presentation_2026_vfinal_pdf",
      "slide": 16,
      "verified": false
    }
  },
  "catalysts": [
    {
      "event": "GRAND CANYON Pivotal Trial Readout",
      "timing": "End of year 2026",
      "importance": "critical",
      "what_to_watch": "NSAA score difference vs placebo at 18 months, powered at >98% for 1.7 point difference",
      "bull_scenario": "Statistically significant and clinically meaningful improvement in NSAA score with good safety profile",
      "bear_scenario": "Failure to meet primary endpoint or significant safety concerns"
    },
    {
      "event": "NDA Submission for Becker",
      "timing": "H1 2027",
      "importance": "critical",
      "what_to_watch": "Successful regulatory filing based on GRAND CANYON results",
      "bull_scenario": "Smooth NDA submission with potential for accelerated review given unmet need",
      "bear_scenario": "Regulatory delays or additional requirements from FDA"
    },
    {
      "event": "Phase 3 Trial Planning and Initiation in Duchenne",
      "timing": "H1 2026",
      "importance": "high",
      "what_to_watch": "Trial design and enrollment initiation",
      "bull_scenario": "Rapid initiation of Phase 3 trial expanding addressable market",
      "bear_scenario": "Delays in trial initiation or regulatory feedback"
    }
  ],
  "investment_analysis": {
    "probability_of_success": null,
    "key_risks": [
      "Pivotal trial failure to meet primary endpoint",
      "Small patient population limits commercial opportunity",
      "Competition from other muscle disease approaches",
      "Regulatory approval challenges"
    ],
    "bull_case": [
      {
        "thesis": "First-ever therapy in Becker with zero competition and Orphan exclusivity",
        "evidence": "No FDA-approved therapies; FDA Type C confirmation of registration path",
        "confidence": "high"
      },
      {
        "thesis": "3 years of durability data from MESA OLE",
        "evidence": "NSAA stabilization diverging from natural history after 3 years",
        "confidence": "medium"
      },
      {
        "thesis": "Duchenne expansion represents much larger market (10mg dose selected)",
        "evidence": "LYNX/FOX Phase 2 data, Phase 3 design H2 2026",
        "confidence": "medium"
      }
    ],
    "bear_case": [
      {
        "thesis": "NSAA endpoint may not translate to meaningful clinical benefit",
        "evidence": "Even 1-point NSAA decline can have detrimental effects, but regulatory acceptance uncertain",
        "confidence": "medium"
      },
      {
        "thesis": "Limited commercial opportunity due to small patient population",
        "evidence": "Only ~6,000 Becker patients in US limits peak sales potential despite high pricing",
        "confidence": "medium"
      }
    ],
    "key_debates": [
      {
        "question": "Will NSAA functional benefit translate to regulatory approval and commercial success?",
        "bull_view": "NSAA preservation is clinically meaningful in progressive disease with no alternatives",
        "bear_view": "Regulatory bar may be higher for functional endpoints in rare disease",
        "what_resolves_it": "GRAND CANYON pivotal trial results and FDA interactions"
      },
      {
        "question": "Can Edgewise successfully execute first commercial launch?",
        "bull_view": "Strong commercial preparation, high physician awareness, clear unmet need",
        "bear_view": "Inexperienced commercial organization in specialized rare disease market",
        "what_resolves_it": "Commercial execution following potential approval"
      }
    ]
  },
  "_extraction_quality": {
    "completeness_score": "high",
    "missing_critical_fields": [
      "PK parameters",
      "Specific dosing for Becker",
      "Detailed safety/AE data",
      "Patient population size (Becker prevalence)",
      "Market TAM",
      "Peak sales estimates",
      "Trial arm details for CANYON/GRAND CANYON",
      "IP/patent expiry"
    ],
    "recommended_supplementary_sources": [
      "Edgewise 10-K for financials and IP",
      "CANYON full publication for detailed efficacy/safety",
      "ClinicalTrials.gov NCT05291091 for GRAND CANYON design",
      "MDA 2025 conference presentation for MESA data"
    ]
  }
}